Nexalin Technology has commenced sales of its second generation 15 milliamp neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder. The new clinic opened and commenced treatment of patients with Nexalin’s Gen-2 neurostimulation device following a successful evaluation and inspection of the facility by the Sultanate of Oman’s Ministry of Health, which ensures strict quality standards and adherence to established and robust guidelines and regulations. As previously announced, Nexalin was recently granted regulatory approval for its Gen-2, 15 milliamp neurostimulation device by the Sultanate of Oman’s Ministry of Health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NXL:
- Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
- Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
- Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
- Nexalin Technology announces results from study of its Gen-2 tACS device
- Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device